Active substances set

Search phrase: idecabtagene vicleucel

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Multiple myeloma and plasma cell neoplasms

Idecabtagene vicleucel	Idecabtagene vicleucel is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	NO REIMBURSEMENT ESMO